MARIETTA, Ga., July 9, 2013 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that the Company will visit the NASDAQ MarketSite in Times Square and ring the Opening Bell on Friday, July 12, 2013. Parker H. "Pete" Petit, Chairman and CEO will perform the honorary ringing of the Opening Bell. Bill Taylor, President and COO; Mike Senken, Chief Financial Officer; Debbie Dean, Executive Vice President; Brent Miller, Executive Vice President; Thornton Kuntz, Vice President Human Resources & Administration; and Mike Carlton, Vice President Global Sales, will be joining Mr. Petit in the ceremony. "Our listing on NASDAQ represents another significant milestone in our strategy to broaden our exposure to the investment community and to increase the trading volume in our stock," said Petit. "Joining the NASDAQ Exchange also comes at an important time for MiMedx as the Company has just become part of the Russell 2000." The Opening Bell will ring at 9:30 am Eastern Daylight Time and will be televised on CNBC or can be viewed online at www.nasdaq.com. About the Company MiMedx® is an integrated developer, manufacturer and marketer of patent protected regenerative biomaterial products and bioimplants processed from human amniotic membrane. " Innovations in Regenerative Biomaterials" is the framework behind our mission to give physicians products and tissues to help the body heal itself. Our biomaterial platform technologies include the device technologies HydroFix® and CollaFix™, and our tissue technologies, AmnioFix® and EpiFix®. Our tissue technologies are processed from human amniotic membrane that is derived from the donated placentas. Through our donor program, mothers delivering full-term Caesarean section births can elect in advance of delivery to donate the placenta in lieu of having it discarded as medical waste. We process the human amniotic membrane utilizing our proprietary PURION® process, to produce a safe, effective and minimally manipulated implant for homologous use. MiMedx® is the leading supplier of amniotic tissue, having supplied over 160,000 allografts to date to distributors and OEMs for application in the Wound Care, Surgical, Sports Medicine, Ophthalmic and Dental sectors of healthcare. www.mimedx.comSafe Harbor Statement This press release includes statements that look forward in time or that express management's beliefs, expectations or hopes. Such statements are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, the impact of the NASDAQ listing on the Company's strategy to broaden its exposure to the investment community and increase the trading volume in the Company's stock. These statements are based on current information and belief, and are not guarantees of future performance. Among the risks and uncertainties that could cause actual results to differ materially from those indicated by such forward-looking statements are that the NASDAQ listing does not have the expected impact on the Company's shareholder base or the trading volume in the Company's stock, and the risk factors detailed from time to time in the Company's periodic Securities and Exchange Commission filings, including, without limitation, its 10-K filing for the fiscal year ended December 31, 2012. By making these forward-looking statements, the Company does not undertake to update them in any manner except as may be required by the Company's disclosure obligations in filings it makes with the Securities and Exchange Commission under the federal securities laws. SOURCE MiMedx Group, Inc.